Revive Therapeutics Ltd. | Income Statement
Fiscal year is July-June. All values CAD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
4.30
6.60
6.20
3.60
3.10
Gross Income
4.30
6.60
6.20
3.60
3.10
SG&A Expense
908.50
2,014.50
2,691.40
1,670.20
1,841.40
EBIT
912.80
2,021.10
2,697.60
1,605.70
1,844.50
Unusual Expense
348.80
15.20
41.40
8.40
-
Interest Expense
1.70
1.80
6.90
4.90
2.70
Pretax Income
1,257.10
2,031.10
2,737.90
1,615.90
1,790.80
Consolidated Net Income
1,257.10
2,031.10
2,737.90
1,615.90
1,790.80
Net Income
1,257.10
2,031.10
2,737.90
1,615.90
1,790.80
Net Income After Extraordinaries
1,257.10
2,031.10
2,737.90
1,615.90
1,790.80
Net Income Available to Common
1,257.10
2,031.10
2,737.90
1,615.90
1,790.80
EPS (Basic)
0.06
0.07
0.11
0.03
0.03
Basic Shares Outstanding
20,411.50
27,429.20
24,236.50
47,687.30
55,873.50
EPS (Diluted)
0.06
0.07
0.11
0.03
0.03
Diluted Shares Outstanding
20,411.50
27,429.20
24,236.50
47,687.30
55,873.50
EBITDA
908.50
2,014.60
2,691.40
1,602.10
1,841.40
Other Operating Expense
-
-
-
68.10
-
Non-Operating Interest Income
6.20
7.10
7.90
3.10
4.50
About Revive Therapeutics
View Profile
